0 0 0 0 0 0 0 0
Sign Up Today X
Thanks for submitting the form.
Stockreport

Allogene Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]

Allogene Therapeutics, Inc. (ALLO)  More Company Research Source: Yahoo! Finance
Last allogene therapeutics, inc. earnings: 2/27 04:30 am Check Earnings Report
reporting top-line MRD clearance in 24 patients (12 per arm) and high-level safety, targeting a conservative 25–30% absolute MRD clearance delta between arms. The Phase 1 ALLO-329 (RESOLUTION) autoimmune study will report initial proof-of-concept translational and early clinical signals in June 2026, testing a low starting dose and the company's “Dagger” technology across cohorts with cyclophosphamide-only versus no lymphodepletion to evaluate persistence without conventional cytotoxic lymphodepletion. Allogene finished 2025 with $258.3M in cash plus a $23.7M escrow release and additional ATM proceeds, which management says extends the company's cash runway into Q1 2028 ; 2026 guidance is ~ $150M operating cash expense and ~ $210M GAAP operating expense. Interested in Allogene Therapeutics, Inc.? Here are five stocks we like better. 3 Stocks With Sky-High Short Interest Levels Allogene Therapeutics (NASDAQ:ALLO) used its fourth-quarter 2025 conference call to outline what ma [Read more]
IMPACT SNAPSHOT EVENT TIME: ALLO
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
ALLO alerts
from News Quantified
ALLO
NEWS
ALLO
Earnings
ALLO
Analyst Actions
ALLO
SEC Filings
Stockreport

Allogene Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]

Allogene Therapeutics, Inc.  (ALLO) 
More Company Research Source: Yahoo! Finance
Last allogene therapeutics, inc. earnings: 2/27 04:30 am Check Earnings Report
reporting top-line MRD clearance in 24 patients (12 per arm) and high-level safety, targeting a conservative 25–30% absolute MRD clearance delta between arms. The Phase 1 ALLO-329 (RESOLUTION) autoimmune study will report initial proof-of-concept translational and early clinical signals in June 2026, testing a low starting dose and the company's “Dagger” technology across cohorts with cyclophosphamide-only versus no lymphodepletion to evaluate persistence without conventional cytotoxic lymphodepletion. Allogene finished 2025 with $258.3M in cash plus a $23.7M escrow release and additional ATM proceeds, which management says extends the company's cash runway into Q1 2028 ; 2026 guidance is ~ $150M operating cash expense and ~ $210M GAAP operating expense. Interested in Allogene Therapeutics, Inc.? Here are five stocks we like better. 3 Stocks With Sky-High Short Interest Levels Allogene Therapeutics (NASDAQ:ALLO) used its fourth-quarter 2025 conference call to outline what ma [Read more]
IMPACT SNAPSHOT
EVENT TIME:
ALLO
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS